文献

1)GuidelinesSubcommittee:1999 World Health Organization-International   SocietyofHyper-tensionGuidelinesforthe Management of Hypertension.J Hypertens 17:151-183,198

2)Draft of the proposed guidelines for the clinical evaluations of antihypertensive drugs.FDA,1988

3)Rose M,McMahon FG:Some problem with antihypertensive drug studies in the context of the new guidelines. Am J Hypertens 3:151-155,1990

4)Muller JE:Morning increase of onset of myocardial infarction.Implications concerning triggering events. Cardiology 76:96-104,1989
5)Parati G, Omboni S, Rizzoni D, Agabiti-Rosei E, mancia G: The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity the blood pressure reduction with treatment for hypertension. J Hypertens 16:1685-1691,1998

6)Vaur L, dubroca I, et al: Superiority of home blood pressure measurements over office measurements for testing antihypertensive drugs: Blood pressure monitoring 3:107-114,1998

7)Liu L, JG, Gong et al: Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 14:1237-1245,1996

8)Staessen JA, Fagard R, Thijs L, et al: Randomised doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350:757-764,1997

9)Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S,M’enard J, Rahn KH, Wedel H, Westerling S for the HOT Study Group. Effects of intensive blood-pressure low-ering and low-dose aspirin in patients with hypertension:principal results of the hypertension Optimal Treatment (HOT)ran-domised trial. Lancet 351:1755-1762,1998                            

10)大久保孝義、辻一郎:家庭血圧の経済効果。血圧。7,385-389,2000